Benefits of cardiopulmonary bypass using a heparin-coating circuit in subclinical plasma coagulation and fibrinolysis

Japanese Journal of Artificial Organs

Volumn 28, Issue 2, 1999, Pages 377-382

  Kamiyashiki, S ^a   Someya, T ^b   Hashimoto, K ^b  

^a SAITAMA CARDIOVASCULAR AND RESPIRATORY CENTER   (Japan)

^b NONE

Author keywords

Cardiopulmonary bypass; Heparin concentration; Heparin coating

Indexed keywords

D DIMER; FIBRINOPEPTIDE A; HEPARIN;

ADULT; AGED; ANTICOAGULATION; BLOOD CLOTTING; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DEVICE; FEMALE; FIBRINOLYSIS; HUMAN; MALE; PLASMA; THROMBOCYTE FUNCTION;

EID: 0032983386     PISSN: 03000818     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (10)

1. von Segesser LK: Reduced blood loss and transfusion requirements with low systemic heparinazation. Preliminary clinical results in coronary Eur J Cardiothorac Surg 4: 639, 1990
2. Gu YJ: Heparin-coating of extracorporeal circuits reduces thrombin formation in patients undergoing cardiopulmonary bypass. Pefusion 6: 220, 1991
3. Hashimoto K: Heparin and antithrombin-III levels during cardiopulmonary bypass: Correlation with subclinical plasma coagulation. Ann Thorac Surg 58: 799, 1994